DSMB Clears PBGENE-DMD Safety Review, Allowing Expanded Dosing in Duchenne Trial
DTIL has more than doubled off its 52-week low of $3.53.
Summary
The independent Data Safety Monitoring Board reviewed the first FUNCTION-DMD patient's eight-week safety data and found no serious adverse events or adverse events of special interest, clearing Precision to dose additional patients in Part 1. That is the key gating step for an AAV-delivered in vivo gene editing program, where early immune and safety signals are the main reason trials stall. The readout is for PBGENE-DMD in Duchenne muscular dystrophy, a separate program from the PBGENE-HBV hepatitis B data released earlier today, so it broadens the clinical story rather than repeating it. The company said it looks forward to safety and efficacy updates from FUNCTION-DMD throughout 2027. Cash of $108.0M with runway guided through 2028, per the Q3 filing, means this program is funded without an immediate raise, though a shelf offering was also filed today.
At the time of this announcement, DTIL was trading at $8.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226.8M. The 52-week trading range was $3.53 to $9.62. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.